DUBAI, KOMPAS.TV – Research in the United Arab Emirates found high-risk patients including adults, pregnant women and children 12 years of age and over with mild to moderate Covid-19 infection survived possible death with the antiviral treatment Sotrovimab.
This includes patients who have a risk that their symptoms can develop into severe, as reported by Arab News, Sunday (18/07/2021)
From the results of a two-week study evaluation of 6,175 Covid-19 patients in Abu Dhabi receiving Sotrovimab treatment, the results showed 100% prevention of deaths, 99% prevention of admission to intensive care units, and 97% of patients making a full recovery within 14 days, UAE health officials said. reported by the official Emirates News Agency, WAM.
In the study, about 52 percent of patients aged 50 years or older, and almost all of the participants who tested positive for Covid-19 had several co-morbidities including obesity, cancer, cardiovascular disease, and diabetes.
Sotrovimab, a monoclonal antibody treatment administered via intravenous therapy, is being produced by global biopharmaceutical company GlaxoSmithKline.
Also Read: Abu Dhabi is now using facial scanners to test for Covid-19
The United Arab Emirates Ministry of Health and Prevention, MoHAP, has approved the use of Sotrovimab after conducting a local evaluation. The drug has also reportedly received emergency use approval from the United States Food and Drug Administration, the FDA.
– .
